The Vaccine and Cervical Cancer Screen project 2 (VACCS 2) : linking cervical cancer screening to a two-dose HPV vaccination schedule in the south-west district of Tshwane, Gauteng, South Africa

Show simple item record

dc.contributor.author Snyman, Leon C.
dc.contributor.author Dreyer, Greta
dc.contributor.author Visser, Carina
dc.contributor.author Botha, M.H.
dc.contributor.author Van der Merwe, F.H.
dc.date.accessioned 2015-03-12T08:53:46Z
dc.date.available 2015-03-12T08:53:46Z
dc.date.issued 2015-03
dc.description.abstract BACKGROUND : Cervical cancer is a preventable disease with a high prevalence in South Africa (SA), where screening is opportunistic. Primary prevention is now possible through HPV vaccination. In VACCS 1 the feasibility of linking cervical cancer with HPV vaccination was demonstrated. OBJECTIVES : To investigate the feasibility of linking HPV self-testing with a two-dose HPV vaccination schedule and to compare results with VACCS 1. METHODS : The project was conducted in five schools in the South-West District of Tshwane, Gauteng, SA. Leaflet information on cervical cancer and screening was provided, with requests for consent and assent for a two-dose HPV vaccination of schoolgirls. Female caregivers were invited to take part in HPV self-screening. RESULTS : Of 965 girls invited for vaccination, 519 (53.7%) had full consent and 518 (99.8%) received at least one vaccine dose. The invited uptake rate was 53.7% and 495 girls received both doses, giving a completion rate of 95.4% v. 82.6% in VACCS 1. Of 1 135 self-screen kits handed out, 560 (49.3%) were not returned. The mean age (standard deviation) of the 160 women who participated in self-screening was 38.7 (7.7) years. HPV testing was negative in 116 women (72.5%), 15 women (9.4%) tested positive for HPV 16 and/or 18, and 27 (16.9%) were positive for non-16/18 oncogenic HPV. CONCLUSION : Data from the VACCS projects suggest that school-based vaccine programmes can be successfully implemented. A two-dose schedule allowed for higher completion rates. Linking self-collected HPV screening to HPV vaccination is feasible, is a promising and viable screening strategy, and reached the appropriate age group for screening. en_ZA
dc.description.librarian hb2015 en_ZA
dc.description.sponsorship Cancer Research Initiative of South Africa,South African Medical Research Council and the Cancer Association of South Africa.First for Women Insurance.GlaxoSmithKline Biologicals SA (117280). en_ZA
dc.description.uri http://www.samj.org.za en_ZA
dc.identifier.citation Snyman, LC, Dreyer, G, Visser, C, Botha, MH & Van der Merwe, FH 2015, 'The Vaccine and Cervical Cancer Screen project 2 (VACCS 2) : linking cervical cancer screening to a two-dose HPV vaccination schedule in the south-west district of Tshwane, Gauteng, South Africa', South African Medical Journal, vol. 105, no. 3, pp. 191-194. en_ZA
dc.identifier.issn 0256-9574 (print)
dc.identifier.issn 2078-5135 (online)
dc.identifier.other 10.7196/SAMJ.8888
dc.identifier.uri http://hdl.handle.net/2263/43939
dc.language.iso en en_ZA
dc.publisher Health and Medical Publishing Group en_ZA
dc.rights © 2015 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). en_ZA
dc.subject Vaccine and Cervical Cancer Screen (VACCS) en_ZA
dc.subject Cervical cancer en_ZA
dc.subject Human papillomavirus (HPV) en_ZA
dc.subject South Africa (SA) en_ZA
dc.subject HPV self-testing en_ZA
dc.subject HPV vaccination en_ZA
dc.title The Vaccine and Cervical Cancer Screen project 2 (VACCS 2) : linking cervical cancer screening to a two-dose HPV vaccination schedule in the south-west district of Tshwane, Gauteng, South Africa en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record